DRIO

DarioHealth Corp. (DRIO) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. DarioHealth Corp. is a global digital therapeutics (DTx) company providing personalized interventions for chronic conditions including diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company operates under a B2B2C model, selling to health plans and employers. A significant event during the period was the acquisition of Twill Inc. on February 15, 2024, to expand its multi-condition platform capabilities.

Key Financial Metrics

Note: Net loss includes significant non-cash financial income of $11.27 million for the six months ended June 30, 2024, primarily due to the revaluation of pre-funded warrants issued for the Twill acquisition.

Material Changes vs. Prior Period

• Revenue: Q2 2024 revenue increased 1.7% year-over-year, while YTD revenue decreased 9.1%. The YTD decline was driven by a $1.09 million price concession recorded in Q2 to resolve a dispute with a preferred partner, offsetting growth from the Twill acquisition.
• Acquisition Impact: The acquisition of Twill contributed $5.54 million in revenue for the six months ended June 30, 2024. Pro forma revenue for the period would have been $13.98 million if the acquisition had occurred on January 1, 2023.
• Expenses: Operating expenses increased significantly due to the consolidation of Twill. R&D expenses rose 29.5% YTD, and Sales & Marketing expenses rose 9.7% YTD.
• Financial Income: The company reported a net financial income of $11.27 million for the six months ended June 30, 2024, compared to financial expenses of $2.98 million in the prior year period. This is largely attributable to a $12.56 million gain from the revaluation of warrant liabilities.
• Workforce Reduction: The company reduced its workforce by 88 employees (approximately 30%) during the quarter to reduce operating expenses.

Outlook, Risks, and Contingencies

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for twelve months from the date of issuance. The company has an accumulated deficit of $363.47 million and expects to incur future net losses.
• Liquidity: Cash and cash equivalents decreased to $22.94 million. The company relies on raising additional funds through debt or equity to fund operations. A $30 million credit facility (Avenue Loan) is in place, with $28.63 million outstanding at fair value.
• Geopolitical Risk: Significant operations are located in Israel. The company faces risks related to the ongoing conflict with Hamas and Hezbollah, including potential employee mobilization, operational disruption, and economic instability.
• Customer Concentration: One major customer accounted for 30.4% of Q2 revenue and 23.7% of YTD revenue. Loss of this customer would materially impact results.
• Stock Volatility: The stock price has been highly volatile, ranging from $0.92 to $2.55 between January and August 2024, which could impact the valuation of intangible assets and goodwill.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $22.94 million cash balance against the projected burn rate, given the "substantial doubt" disclosure.
• Warrant Liability Volatility: Assess the impact of the $12.05 million warrant liability on future earnings, as revaluations can cause significant non-cash swings in net income/loss.
• Customer Concentration: Review the status of the contract with the major customer (29.7% of receivables) and the resolution of the dispute that led to the $1.09 million revenue reduction.
• Debt Covenants: Confirm compliance with the Avenue Loan Facility covenants, specifically the requirement to maintain $5.0 million in unrestricted cash.
• Goodwill Impairment: Monitor the $57.43 million goodwill balance for potential impairment triggers given the stock price volatility and operating losses.